Does HD's Damage Start in the Epigenome — Before Symptoms?
Experiment #8 | June 29, 2026
Experiment Card
Is DNA methylation dysregulation (loss of the enzyme TET1) a pre-symptomatic driver of HD — and can a simple cofactor like Vitamin C help restore it?
How It Connects to Experiment #7
Experiment #7 found lipid raft disruption is the first event in HD. Experiment #8 adds a parallel early track: TET1 suppression silences DNA-demethylation before symptoms. The two likely reinforce each other — lipid/metabolic stress depletes the cofactors epigenetic enzymes need, and failing epigenetic control further weakens the cell's ability to maintain membranes and clear proteins.
Top Findings
TET1 suppression is an early molecular event preceding clinical HD symptoms (knock-in pig model, PMID 42322611), opening a pre-symptomatic intervention window.
The lipid-proteostasis cascade (Exp 7) and epigenetic failure are interconnected: lipid stress → proteotoxic burden → impaired TET/DNA methylation → transcriptional dysregulation.
Ascorbate (Vitamin C) is the most mechanistically sound, low-risk candidate — it's a direct cofactor for TET enzymes, so restoring levels could reactivate DNA demethylation.
Drug Candidates
| Candidate | Target | Score | Repurposing path |
|---|---|---|---|
| Ascorbate (Vitamin C) | TET cofactor | 90/100 | Oral supplement, widely available |
| Decitabine | DNMT inhibition | 75/100 | Approved for MDS — but global effect, needs localized delivery |
| Lipid-modulating agents | Membrane / raft integrity | 95/100 | Addresses the Exp 7 primary trigger (see CYP46A1) |
Note: Ascorbate's high score reflects mechanistic plausibility + safety, not proven clinical efficacy in HD. Always disclaim — this is a research hypothesis, not a treatment recommendation.
Novel Hypotheses Generated
Lipid-induced membrane stress depletes NAD+, compromising SIRT3, which destabilizes TET1/DNA demethylation — linking metabolism to the epigenome.
How to test: Measure NAD+/NADH ratios and SIRT3 activity in HD patient-derived neurons after acute lipid raft disruption.
PolyQ HTT aggregates directly sequester epigenetic enzymes (DNMTs, HDACs), causing a secondary failure in DNA repair and chromatin remodeling.
How to test: Co-IP / mass-spec on HTT aggregates from HD patient tissue to identify sequestered epigenetic modifiers.
Experiment #9: Combination Therapy
Test the synergy of restoring lipid raft integrity (Exp 7) and providing TET1 cofactor support (ascorbate, Exp 8). Treat HD models with combination therapy targeting both membrane stability and DNA demethylation, and measure rescue of proteostasis markers — reduced ubiquitinated aggregates, improved mitochondrial respiration.
Experiment Trail
This analysis is AI-generated for educational purposes only. Not clinical advice. Vitamin C / ascorbate is discussed as a research hypothesis about TET enzyme biology, not a treatment recommendation — do not self-medicate. All findings should be verified against primary literature. Data: PubMed (last 24 months). Model: Gemma 4, local inference. We are data scientists, not doctors.